Sweet Bomb
A Bomb Seeds hybrid marketed as a heavy-yielding, sugary indica-leaning strain with modest THC and a sweet-fruit profile.
Sweet Bomb is a commercial seed-bank hybrid from Bomb Seeds, not a legendary heritage cultivar. What's real: it's a photoperiod hybrid sold widely in Europe, it flowers reasonably fast, and growers generally report solid yields. What's marketing: the specific 'sweet candy' effect claims, the tidy THC percentages on the seed page, and the confident indica/sativa split. There is no published chemistry work on this cultivar, no clinical data, and the parent lineage is not publicly documented. Treat everything below as breeder-reported unless noted.
Overview
Sweet Bomb is a commercial cannabis strain released by Bomb Seeds, a Dutch seed bank known for its '-Bomb' branded lineup (Big Bomb, THC Bomb, Cherry Bomb, etc.) [1]. It is sold in both photoperiod and autoflower formats. The strain is marketed as a sweet-tasting, easy-to-grow hybrid aimed at commercial and home growers who prioritize yield and short flowering time over boutique cannabinoid or terpene profiles.
Unlike heritage cultivars such as Northern Lights or Haze, Sweet Bomb has no significant presence in cannabis competitions, no published chemotype data, and limited independent grower documentation outside seed-bank affiliate reviews. It is best understood as a functional production strain rather than a culturally significant one.
Chemistry: cannabinoids and terpenes
There is no peer-reviewed or independent laboratory characterization of Sweet Bomb's cannabinoid or terpene content that we could locate No data. All available numbers come from the breeder's own marketing copy [1].
Breeder claims:
- THC: approximately 15–19%
- CBD: negligible (<1%), consistent with the vast majority of modern high-THC hybrids [2]
- Terpene profile: described qualitatively as 'sweet,' 'fruity,' and 'candy-like' — descriptors that in other cultivars often correlate with terpenes like myrcene, limonene, or terpinolene, but this correlation has not been measured for Sweet Bomb specifically No data.
Until an independent lab publishes a chemotype, treat any specific terpene ranking (e.g. 'myrcene-dominant') as guesswork. The popular idea that a specific myrcene percentage flips a strain from 'sativa' to 'indica' effects is folklore, not established science [3] Disputed.
Reported effects
Bomb Seeds and affiliated retailers describe Sweet Bomb as producing a 'relaxing,' 'body-heavy,' and 'mood-lifting' effect [1]. Grower forum posts echo similar language Anecdote.
Important caveats:
- There are no clinical trials on Sweet Bomb or any other single commercial strain. Published cannabis pharmacology studies use isolated cannabinoids, standardized extracts, or pooled flower — not branded cultivars [2][evidence:none for strain-specific claims].
- The indica vs. sativa framework is a poor predictor of subjective effects. Chemotype (cannabinoid + terpene profile) predicts effects better than lineage labels, and even that is only a rough guide [3][4] Strong evidence.
- Individual response varies dramatically with dose, tolerance, set, setting, and consumption method.
In short: expect a moderately strong THC-dominant flower. Whether it feels 'sweet and relaxing' to you personally is not something a seed listing can predict.
Lineage
Bomb Seeds does not publicly disclose Sweet Bomb's parent genetics [1] Disputed. The company generally describes its lineup as built on undisclosed 'Bomb' backcrosses combined with unnamed imported genetics.
Some third-party strain databases speculate about parents (variously naming Sweet Tooth, Big Bomb, or generic 'sweet indica' crosses), but these entries are user-submitted and unsourced. Without breeder confirmation or genetic sequencing (e.g. the kind of work done by Phylos Bioscience or academic groups [5]), any specific pedigree claim for Sweet Bomb should be treated as unverified.
This is common in the seed-bank industry: a large fraction of commercial strain lineages are marketing narratives rather than documented breeding records [5] Strong evidence.
Cultivation basics
Per breeder documentation [1]:
- Flowering time: 8–9 weeks indoors under a 12/12 photoperiod.
- Yield: around 500–550 g/m² indoors under competent conditions; outdoor yields reported higher in warm climates.
- Structure: medium height, indica-leaning bush habit, responsive to topping and low-stress training.
- Climate: finishes reliably in temperate European outdoor conditions by early October.
- Difficulty: marketed as beginner-friendly; no unusual nutrient sensitivities reported.
These numbers are typical for modern commercial photoperiod hybrids and are not exceptional in either direction. Real-world yields depend far more on light intensity, VPD, feeding, and grower skill than on genetics alone Strong evidence.
Marketing vs. reality
What Bomb Seeds' listing tells you honestly:
- It's a photoperiod hybrid with sweet-leaning aromatics.
- It yields well and finishes in a normal indoor timeframe.
What's overstated or unverifiable:
- Precise THC percentages. Seed-bank THC numbers are typically best-case lab results from a single well-grown pheno, not averages you should expect at home [6] Strong evidence.
- Indica/sativa effect predictions. Modern genomics shows the indica/sativa split does not map cleanly onto chemistry or effects [4] Strong evidence.
- 'Sweet candy' flavor descriptors. Aroma varies by phenotype, cure, and grow environment; expect variation between seeds from the same pack.
- Lineage. Undisclosed, so any pedigree diagram you see online for Sweet Bomb is speculation.
Bottom line: Sweet Bomb is a reasonable choice if you want a fast, forgiving, decent-yielding sweet-smelling hybrid from a mid-tier European seed bank. It is not a boutique or medically-characterized cultivar, and you should ignore any confident claims about its specific effects.
Sources
- Practitioner Bomb Seeds. 'Sweet Bomb' product page and strain description. Bomb Seeds official catalog.
- Peer-reviewed ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. Biological Psychiatry. 2016;79(7):613-619.
- Peer-reviewed Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-1364.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLoS ONE. 2022;17(5):e0267498.
- Peer-reviewed Sawler J, Stout JM, Gardner KM, Hudson D, Vidmar J, Butler L, Page JE, Myles S. The Genetic Structure of Marijuana and Hemp. PLoS ONE. 2015;10(8):e0133292.
- Peer-reviewed Jikomes N, Zoorob M. The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. Scientific Reports. 2018;8:4519.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Myrcene — The most common monoterpene in cannabis, blamed and credited for a lot of things it probab...